Daily News
Daily News

Impact of benzodiazepine consumption reduction on future burden of dementia

Mental Health News Daily

2020 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health News Daily -- New research on Neurodegenerative Diseases and Conditions - Dementia is the subject of a report. According to news reporting originating in Bordeaux, France, by NewsRx journalists, research stated, “Dementia is a major public health issue worldwide and chronic use of benzodiazepine, which is very frequent in northern countries, was found to be a risk factor of dementia. This work aims at evaluating the impact of a reduction in chronic use of benzodiazepine on the future burden of dementia in France.”

The news reporters obtained a quote from the research from the University of Bordeaux, “Using estimations of dementia incidence and of benzodiazepine use and nation-wide projections of mortality and population sizes, a Monte Carlo approach based on an illness-death model provided projections of several indicators of dementia burden. With no change in benzodiazepine consumption, the prevalence of dementia between age 65 and 99 in France in 2040 was estimated at 2.16 millions (95% confidence interval (CI) 1.93-2.38), with a life expectancy without dementia at 65 years equal to 25.0 years (24.7-25.3) for women and 23.8 years (23.5-24.2) for men. Assuming a disappearance of chronic use of benzodiazepine in 2020, the prevalence would be reduced by about 6.6% in 2040 and the life expectancy without dementia would increase by 0.99 (0.93-1.06) year among women and 0.56 (0.50-0.62) among men.”

According to the news reporters, the research concluded: “To conclude, a modest but significant reduction in future dementia burden could be obtained by applying current recommendation for duration of benzodiazepine use.”

For more information on this research see: Impact of benzodiazepine consumption reduction on future burden of dementia. Scientific Reports, 2020;10(1):14666. (Nature Publishing Group - http://www.nature.com/; Scientific Reports - http://www.nature.com/srep/)

Our news correspondents report that additional information may be obtained by contacting Helene Jacqmin-Gadda, French National Institute of Health and Medical Research (INSERM), ISPED, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, Bordeaux, France. Additional authors for this research include Florian Guillet, Clement Mathieu, Catherine Helmer, Antoine Pariente and Pierre Joly.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/s41598-020-71482-0. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)